Summary
24.75 0.00(0.00%)06/28/2024
Smith & Nephew plc (SNN)
Smith & Nephew plc (SNN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.02 | -2.29 | -0.62 | -2.41 | -9.37 | -22.41 | -38.73 | 442.21 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.75 | |
| Open | 24.74 | |
| High | 24.85 | |
| Low | 24.69 | |
| Volume | 566,862 | |
| Change | -0.00 | |
| Change % | -0.02 | |
| Avg Volume (20 Days) | 509,685 | |
| Volume/Avg Volume (20 Days) Ratio | 1.11 | |
| 52 Week Range | 21.53 - 32.28 | |
| Price vs 52 Week High | -23.33% | |
| Price vs 52 Week Low | 14.96% | |
| Range | 0.04 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 10,803 | |
| EBIDTA | 1,116,999,936 | |
| PE Ratio | 42.0333 | |
| PEG Ratio | 0.4494 | |
| WallStreet Target Price | 30.50 | |
| Book Value | 5.9840 | |
| Earnings Per Share | 0.6000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 1.2500 | |
| EPS Estimate Next Year | 1.5100 | |
| Diluted EPS (TTM) | 0.6000 | |
| Revenues | ||
| Profit Marging | 0.0474 | |
| Operating Marging (TTM) | 0.1446 | |
| Return on asset (TTM) | 0.0427 | |
| Return on equity (TTM) | 0.0502 | |
| Revenue TTM | 5,549,000,192 | |
| Revenue per share TTM | 2.5484 | |
| Quarterly Revenue Growth (YOY) | 0.0760 | |
| Quarterly Earnings Growth (YOY) | 0.9830 | |
| Gross Profit (TTM) | 3,695,000,000 | |
| Dividends | ||
| Dividend Share | 0.3750 | |
| Dividend Yield | 0.0297 | |
| Valuations | ||
| Trailing PE | 42.0333 | |
| Forward PE | 12.0773 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9918 | |
| Revenue Enterprise Value | 2.4027 | |
| EBITDA Enterprise Value | 13.9462 | |
| Shares | ||
| Shares Outstanding | 437,172,992 | |
| Shares Float | 862,752,855 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.03 | |
| Institutions (%) | 7.50 | |
06/14 14:35 EST - zacks.com
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
06/11 20:38 EST - seekingalpha.com
Smith & Nephew: Work To Be Done But Still Long-Term Potential
Smith & Nephew's share price has increased by 14% since September 2022, indicating undervaluation. The company showed decent top line growth with a 6.4% increase in revenue last year. While the company's growth plans are transforming the business, there are concerns about the actual performance and management quality.
Smith & Nephew: Work To Be Done But Still Long-Term Potential
Smith & Nephew's share price has increased by 14% since September 2022, indicating undervaluation. The company showed decent top line growth with a 6.4% increase in revenue last year. While the company's growth plans are transforming the business, there are concerns about the actual performance and management quality.
05/20 05:04 EST - https://www.defenseworld.net
National Bank of Canada FI Has $53,000 Stake in Smith & Nephew plc (NYSE:SNN)
National Bank of Canada FI lifted its position in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 36.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,967 shares of the medical equipment provider’s stock after buying an additional 521 shares during the period. National Bank of Canada FI’s holdings in Smith & Nephew were worth $53,000 at the end of the most recent quarter. Other institutional investors and hedge funds also recently modified their holdings of the company. Scharf Investments LLC boosted its position in shares of Smith & Nephew by 20.5% during the fourth quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock worth $81,304,000 after buying an additional 506,474 shares during the period. PNC Financial Services Group Inc. grew its stake in Smith & Nephew by 17.4% in the third quarter. PNC Financial Services Group Inc. now owns 36,315 shares of the medical equipment provider’s stock valued at $900,000 after purchasing an additional 5,384 shares in the last quarter. Seed Wealth Management Inc. acquired a new position in shares of Smith & Nephew during the 4th quarter worth approximately $213,000. London & Capital Asset Management Ltd bought a new stake in shares of Smith & Nephew during the 4th quarter worth approximately $1,054,000. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Smith & Nephew by 38.8% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 245,609 shares of the medical equipment provider’s stock worth $6,700,000 after purchasing an additional 68,609 shares in the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds. Smith & Nephew Stock Up 0.9 % Shares of NYSE:SNN opened at $26.09 on Monday. Smith & Nephew plc has a 52-week low of $21.52 and a 52-week high of $32.36. The company has a current ratio of 1.77, a quick ratio of 0.72 and a debt-to-equity ratio of 0.44. The company has a 50-day simple moving average of $25.21 and a 200 day simple moving average of $26.29. Smith & Nephew Dividend Announcement The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd will be given a $0.462 dividend. The ex-dividend date of this dividend is Monday, April 1st. This represents a dividend yield of 2.8%. Wall Street Analyst Weigh In Separately, StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”. View Our Latest Stock Analysis on Smith & Nephew About Smith & Nephew (Free Report) Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. Read More Five stocks we like better than Smith & Nephew Canada Bond Market Holiday: How to Invest and Trade MarketBeat Week in Review – 5/13 – 5/17 What is a Special Dividend? Take-Two Interactive Software Offers 2nd Chance for Investors Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
National Bank of Canada FI Has $53,000 Stake in Smith & Nephew plc (NYSE:SNN)
National Bank of Canada FI lifted its position in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 36.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,967 shares of the medical equipment provider’s stock after buying an additional 521 shares during the period. National Bank of Canada FI’s holdings in Smith & Nephew were worth $53,000 at the end of the most recent quarter. Other institutional investors and hedge funds also recently modified their holdings of the company. Scharf Investments LLC boosted its position in shares of Smith & Nephew by 20.5% during the fourth quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock worth $81,304,000 after buying an additional 506,474 shares during the period. PNC Financial Services Group Inc. grew its stake in Smith & Nephew by 17.4% in the third quarter. PNC Financial Services Group Inc. now owns 36,315 shares of the medical equipment provider’s stock valued at $900,000 after purchasing an additional 5,384 shares in the last quarter. Seed Wealth Management Inc. acquired a new position in shares of Smith & Nephew during the 4th quarter worth approximately $213,000. London & Capital Asset Management Ltd bought a new stake in shares of Smith & Nephew during the 4th quarter worth approximately $1,054,000. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Smith & Nephew by 38.8% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 245,609 shares of the medical equipment provider’s stock worth $6,700,000 after purchasing an additional 68,609 shares in the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds. Smith & Nephew Stock Up 0.9 % Shares of NYSE:SNN opened at $26.09 on Monday. Smith & Nephew plc has a 52-week low of $21.52 and a 52-week high of $32.36. The company has a current ratio of 1.77, a quick ratio of 0.72 and a debt-to-equity ratio of 0.44. The company has a 50-day simple moving average of $25.21 and a 200 day simple moving average of $26.29. Smith & Nephew Dividend Announcement The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd will be given a $0.462 dividend. The ex-dividend date of this dividend is Monday, April 1st. This represents a dividend yield of 2.8%. Wall Street Analyst Weigh In Separately, StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”. View Our Latest Stock Analysis on Smith & Nephew About Smith & Nephew (Free Report) Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. Read More Five stocks we like better than Smith & Nephew Canada Bond Market Holiday: How to Invest and Trade MarketBeat Week in Review – 5/13 – 5/17 What is a Special Dividend? Take-Two Interactive Software Offers 2nd Chance for Investors Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/01 15:14 EST - seekingalpha.com
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Caitlin Cronin - Canaccord Genuity Hassan Al-Wakeel - Barclays Julien Dormois - Jefferies Veronika Dubajova - Citi Dylan Van Haaftan - Stifel David Adlington - JPMorgan Sezgi Ozener - HSBC Deepak Nath Good morning, and welcome to the Smith & Nephew Q1 2024 Results Presentation. As mentioned, I'm Deepak Nath.
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Caitlin Cronin - Canaccord Genuity Hassan Al-Wakeel - Barclays Julien Dormois - Jefferies Veronika Dubajova - Citi Dylan Van Haaftan - Stifel David Adlington - JPMorgan Sezgi Ozener - HSBC Deepak Nath Good morning, and welcome to the Smith & Nephew Q1 2024 Results Presentation. As mentioned, I'm Deepak Nath.
05/01 03:53 EST - proactiveinvestors.co.uk
Smith & Nephew tops Footsie after bullish sales update
Smith & Nephew jumped to the top of the FTSE 100 as the UK MedTech delivered a confident first-quarter update and reiterated revenues would grow strongly over the remainder of the year. Sales were up by 2.9% on an underlying basis to US$1.39 billion, helped by good performances from orthopaedics (4.4%) and sports medicine (5.5%) with wound management seeing a fall.
Smith & Nephew tops Footsie after bullish sales update
Smith & Nephew jumped to the top of the FTSE 100 as the UK MedTech delivered a confident first-quarter update and reiterated revenues would grow strongly over the remainder of the year. Sales were up by 2.9% on an underlying basis to US$1.39 billion, helped by good performances from orthopaedics (4.4%) and sports medicine (5.5%) with wound management seeing a fall.
04/12 13:30 EST - seekingalpha.com
U.K. Top 40 Quality Dividend Stocks: Q2 2024
The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary consideration.
U.K. Top 40 Quality Dividend Stocks: Q2 2024
The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary consideration.
04/11 10:16 EST - zacks.com
Smith+Nephew (SNN) Expands in Australia With New Alliance
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Smith+Nephew (SNN) Expands in Australia With New Alliance
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
04/08 18:00 EST - globenewswire.com
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons - and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments.
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons - and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments.
04/04 11:13 EST - globenewswire.com
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT).
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT).
04/01 08:00 EST - globenewswire.com
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients' daily activities.1
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients' daily activities.1
03/25 08:00 EST - globenewswire.com
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies.
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies.
03/13 16:30 EST - investorplace.com
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.
03/11 10:25 EST - proactiveinvestors.co.uk
Smith & Nephew: Scepticism has been overplayed, says leading investment bank
JP Morgan has spotlighted Smith & Nephew PLC (LSE:SN) for its revenue acceleration and margin expansion potential, setting a price target of 1,300p - a 21% premium to the current stock price. Despite investor scepticism, the bank has added S&N to its Analyst Focus List (AFL), highlighting its attractive risk-reward profile in the healthcare sector.
Smith & Nephew: Scepticism has been overplayed, says leading investment bank
JP Morgan has spotlighted Smith & Nephew PLC (LSE:SN) for its revenue acceleration and margin expansion potential, setting a price target of 1,300p - a 21% premium to the current stock price. Despite investor scepticism, the bank has added S&N to its Analyst Focus List (AFL), highlighting its attractive risk-reward profile in the healthcare sector.
02/28 01:13 EST - seekingalpha.com
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript
02/27 03:08 EST - proactiveinvestors.com
Smith & Nephew profits meet targets, 'robust' growth expected in 2024
Smith & Nephew PLC (LSE:SN) kept its dividend unchanged and guided to solid growth this year as it reported 2023 results in line with improved guidance from last summer. The hip and knee replacement specialist posted results showing $5.55 billion of revenue for the past calendar year, up 7.2% on an underlying basis and 6.4% reported.
Smith & Nephew profits meet targets, 'robust' growth expected in 2024
Smith & Nephew PLC (LSE:SN) kept its dividend unchanged and guided to solid growth this year as it reported 2023 results in line with improved guidance from last summer. The hip and knee replacement specialist posted results showing $5.55 billion of revenue for the past calendar year, up 7.2% on an underlying basis and 6.4% reported.
02/21 16:40 EST - investorplace.com
3 Millionaire-Maker Robotics Stocks to Buy in February 2024
There are some key robotics stocks for investors to buy in February. This is amid the broader indices such as the Nasdaq making a brief pullback.
3 Millionaire-Maker Robotics Stocks to Buy in February 2024
There are some key robotics stocks for investors to buy in February. This is amid the broader indices such as the Nasdaq making a brief pullback.
02/21 10:46 EST - zacks.com
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
02/13 08:00 EST - globenewswire.com
Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1
Smith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual Meeting
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1
02/12 15:00 EST - globenewswire.com
Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting
Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* for its CORI◊ Surgical System, this exclusive image-agnostic* robotic-assisted surgical solution is designed to further help personalize surgery, advance efficiencies, and optimize performance across Smith+Nephew's orthopaedic reconstruction portfolio.
Smith+Nephew to showcase leading, innovative AI-driven robotic-assisted solutions for personalized orthopaedic surgery at AAOS 2024 Annual Meeting
Smith+Nephew (LSE: SN, NYSE:SNN), the global medical technology company, announces it will provide a glimpse into the future at AAOS 2024. With a first opportunity to see a forthcoming new feature* for its CORI◊ Surgical System, this exclusive image-agnostic* robotic-assisted surgical solution is designed to further help personalize surgery, advance efficiencies, and optimize performance across Smith+Nephew's orthopaedic reconstruction portfolio.
02/12 08:00 EST - globenewswire.com
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant alongside the REGENETEN◊ Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.1,2 CARTIHEAL AGILI-C◊ Cartilage Repair Implant – a simple, single surgery to repair cartilage and restore bone The CARTIHEAL AGILI-C implant is an accessible, one-step treatment for osteochondral (bone and cartilage) lesions that does not require donor tissue.
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant alongside the REGENETEN◊ Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.1,2 CARTIHEAL AGILI-C◊ Cartilage Repair Implant – a simple, single surgery to repair cartilage and restore bone The CARTIHEAL AGILI-C implant is an accessible, one-step treatment for osteochondral (bone and cartilage) lesions that does not require donor tissue.